Compare Abbott Laboratories (ABT) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Ferrari NV — how do they compare? Abbott Laboratories trades at $111.09 (market cap $187.95B), while Ferrari NV trades at $406.31 (market cap $71.67B). The key difference: Abbott Laboratories is far larger — about 2.6× Ferrari NV's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | RACE | |
|---|---|---|
Market Cap | $187.95B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $504.09 |
52-Week Low | $82.57 | $314.63 |
Enterprise Value | $214.96B | $73.60B |
Dividend Yield | 2.32% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Ferrari (RACE) trades at $405.73, down 0.26% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, reaching $7.15B in 2025, with a net income margin of 22.25% and high profitability metrics like a 45.45% ROE.
The outlook remains positive given strong order books, margin expansion, and analyst consensus favoring a buy rating with a $462.67 price target. Key risks include premium valuation multiples limiting upside and sensitivity to luxury demand cycles. The stock's proximity to its 52-week high suggests momentum but warrants caution on overextension.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
